Ghrelin
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Endogenous 28-amino acid orexigenic hormone and GH secretagogue; the natural ligand for GHS-R1a that explains why ipamorelin, MK-677, GHRP-2, and GHRP-6 work.
Quick Facts
| Property | Value |
|---|---|
| Also Known As | Lenomorelin (INN), "hunger hormone" |
| Category | GH Axis / Endogenous reference peptide |
| Sequence | GSSFLSPEHQRVQQRKESKKPPAKLQPR (28 aa; octanoylated at Ser3) |
| Molecular Weight | ~3371 Da (acylated form) |
| Molecular Formula | C₁₄₉H₂₄₉N₄₅O₄₂ |
| PubChem CID | 10096344 |
| Administration | Not used therapeutically (IV/SubQ in research only) |
| Typical Dose Range | Not applicable — endogenous reference; research doses: 1-5 mcg/kg IV |
| Half-Life | ~30 minutes (acyl-ghrelin); des-acyl ghrelin ~10 min |
| Storage | Research-grade: lyophilized, -20 C |
| FDA Status | Not a drug product; endogenous hormone. No FDA-approved ghrelin products (analogs/mimetics are separate) |
| WADA Status | GH secretagogues are prohibited (S2 class) |
Mechanism of Action
Ghrelin is the endogenous ligand for the growth hormone secretagogue receptor type 1a (GHS-R1a), a G-protein coupled receptor (GPCR) that couples primarily to Gq/11 signaling. Ghrelin was discovered in 1999 by Kojima et al. in rat stomach extracts, resolving the decade-long search for the natural ligand of the previously orphaned GHS-R (PMID-10604470).
Ghrelin's essential structural feature is the octanoyl (C8:0) fatty acid modification at Ser3, catalyzed by the enzyme ghrelin O-acyltransferase (GOAT). This acylation is absolutely required for GHS-R1a binding and GH-releasing activity. Without it, the peptide is called "des-acyl ghrelin" which may have distinct biological activities through unknown receptors.
GH release pathway: Ghrelin binds GHS-R1a on pituitary somatotrophs, activating Gq → PLC → IP3/DAG → intracellular calcium release → GH vesicle exocytosis. Critically, ghrelin acts synergistically with GHRH — ghrelin amplifies the GH pulse initiated by GHRH rather than acting independently. This synergy occurs because GHRH signals through Gs/cAMP while ghrelin signals through Gq/calcium, and both pathways converge on GH secretion (PMID-15788704).
Appetite pathway: Ghrelin crosses the blood-brain barrier and activates GHS-R1a on NPY/AgRP neurons in the arcuate nucleus of the hypothalamus, stimulating appetite and food-seeking behavior. This is independent of GH release. Ghrelin is the only known circulating orexigenic hormone — it rises before meals and falls after eating (PMID-22385874).
Other functions: Gastric motility stimulation (via vagal afferents), gastric acid secretion, cardiovascular effects (vasodilation, increased cardiac output), glucose metabolism modulation, bone metabolism, reward processing, and stress/anxiety modulation.
Key Research Areas
- GH secretagogue receptor biology — Ghrelin discovery explained the mechanism of synthetic GH secretagogues (PMID-10604470)
- Appetite and energy homeostasis — Only known circulating hunger hormone; key regulator of meal initiation (PMID-22385874)
- GH axis synergy — Ghrelin + GHRH synergy explains why CJC-1295/Ipamorelin combinations are superior (PMID-15788704)
- Cachexia/anorexia — Ghrelin analogs explored for cancer cachexia, COPD, heart failure-related wasting
- Gastroparesis — Ghrelin's prokinetic effects studied for functional GI disorders
- GHS-R constitutive activity — Receptor signals at ~50% maximal without ligand, relevant for inverse agonist drug design
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human RCTs | Limited | Mostly proof-of-concept studies for cachexia, gastroparesis |
| Systematic reviews | Several | Appetite, GH secretion, gastroparesis reviews |
| Human observational | Many | Endocrine physiology studies |
| Animal in vivo | Extensive | Foundation of ghrelin biology |
| In vitro | Extensive | Receptor pharmacology, signaling |
Clinical Applications
- Sarcopenia — Ghrelin axis relevant to muscle-wasting conditions
- Fat Loss — Ghrelin physiology context for weight management
- Weight Management — Understanding hunger hormone in obesity
Protocols Using This Peptide
Ghrelin itself is not used in clinical protocols. Its receptor (GHS-R1a) is the target for:
- GH Optimization Protocol — Via ipamorelin, MK-677
- Wolverine Stack Protocol — Indirect relevance via GH axis
Ageless Peps Products
Ghrelin is an endogenous hormone and is NOT sold as a product. The following Ageless Peps products work through ghrelin's receptor (GHS-R1a):
- Ipamorelin — Selective GHS-R1a agonist (most selective synthetic ghrelin mimetic)
- MK-677 — Oral non-peptide GHS-R1a agonist
- CJC-1295 NO DAC / Ipamorelin blend — Combines GHRH analog + ghrelin mimetic for synergistic GH release
Dosing Reference
Research Dosing (not clinical use)
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| IV bolus | 1-5 mcg/kg | Single dose (research) | Acute studies | Various research protocols |
| SubQ | 1-3 mcg/kg | Variable | Research only | Preclinical studies |
Cycling
Not applicable — ghrelin is an endogenous hormone with pulsatile secretion (rises pre-prandially, falls post-prandially).
Contraindications & Safety
- Contraindications: Not applicable (endogenous hormone; not used therapeutically)
- Side effects of exogenous administration: Hunger, increased food intake, mild hyperglycemia, GH elevation
- Drug interactions: N/A for endogenous; GHS-R1a agonists may interact with somatostatin analogs (opposing effects on GH)
- Pregnancy/nursing: Endogenous ghrelin plays role in fetal development
- Special populations: Ghrelin levels are altered in anorexia nervosa (elevated), obesity (reduced), post-bariatric surgery (reduced)
Synergistic Combinations
Understanding ghrelin's synergy with GHRH explains clinical peptide combinations:
- Ghrelin pathway (Ipamorelin) + GHRH pathway (CJC-1295 NO DAC) → Synergistic GH release (the basis for CJC/Ipamorelin blend)
- Ghrelin pathway (Ipamorelin) + GHRH pathway (Tesamorelin) → Synergistic GH release (Tesamorelin/Ipamorelin blend)
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| 10604470 | Ghrelin Discovery: GH-Releasing Peptide from Stomach (Nature) | 1999 | In vitro / Animal |
| 22385874 | Ghrelin: Physiological Significance and Clinical Applications | 2012 | Narrative Review |
| 15788704 | Ghrelin: Structure and Function (Endocrine Reviews) | 2004 | Narrative Review |
References
- PMID-10604470 — Kojima et al., Ghrelin discovery, Nature 1999
- PMID-22385874 — Stengel & Tache, Ghrelin physiology review, Curr Pharm Des 2012
- PMID-15788704 — van der Lely et al., Ghrelin structure and function, Endocr Rev 2004
Related
Educational Note: Ghrelin is an endogenous hormone included in this vault for educational purposes. Understanding ghrelin physiology is essential for comprehending the mechanisms of GH secretagogue peptides used in clinical practice.
#peptide #gh-axis #endogenous #not-sold